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Mechanisms of Carbapenem Resistance
in Multidrug-Resistant Clinical Isolates
of Pseudomonas aeruginosa from a Croatian Hospital
Marina Bubonja-Sonje,1,2 Mihaela Matovina,1 Ivana Skrobonja,2 Branka Bedenic,3,4 and Maja Abram1,2
Pseudomonas aeruginosa is an opportunistic pathogen, one of the leading causes of nosocomial infections such
as pneumonia, urinary tract infections, and bacteraemia. The bacterial resistance to structurally unrelated
antibiotics and its spread within hospitals limits the efficient antimicrobial options and patients’ outcome.
Carbapenems are important agents for the therapy of infections due to multidrug-resistant (MDR) P. aerugi-
nosa; hence, the development of carbapenem resistance severely hampers effective therapeutic options. The aim
of this investigation was to examine mechanisms of carbapenem resistance and genomic diversity in carbapenem-
resistant MDR strains of P. aeruginosa, which caused an outbreak among patients in Clinical Hospital Rijeka.
Most of the isolates showed decreased expression of porin that is important for the entry of carbapenems (oprD).
Overexpression of MexAB-OprM, MexCD-OprJ, and MexEF-OprN efflux systems was observed in many of the
isolates. Production of metallo-b-lactamases was not detected. Typing by pulsed-field gel electrophoresis dis-
criminated the isolates into five clusters. The clonal distribution of the strains was related to the location of hospital
departments where the isolates were collected, which implies that most of the infections were caused by spread of
the epidemic strains within the hospital.
Introduction
Pseudomonas aeruginosa is an important opportunisticpathogen, characterized by environmental versatility and
ability to cause a wide range of human infections in susceptible
individuals. In addition to being intrinsically resistant to sev-
eral antimicrobials, this bacterial species often acquires vari-
ous mechanisms of resistance to other antibiotics.38 Antibiotic
selection pressure represents the leading risk factor for
multidrug-resistant (MDR) acquisition. MDR is defined as
‘‘acquired nonsusceptibility to at least one agent in three
or more antimicrobial categories (aminoglycosides, carba-
penems, antipseudomonal cephalosporins, fluoroquinolones,
antipseudomonal penicillins/b-lactamase inhibitors, mono-
bactams, phosphonic acids, polymyxins).’’27
The increasing frequency of MDR P. aeruginosa strains
in hospital environment is a major concern due to limited
treatment options. Since carbapenems are important agents
for the therapy of infections caused by MDR P. aeruginosa,
the development of carbapenem resistance additionally re-
duces effective therapeutic options. Resistance to carbape-
nems can be due to decreased uptake, increased efflux,
inactivation enzymes, or modified target.25 However, the re-
sistance patterns to individual carbapenems can vary consid-
erably among clinical strains as a result of complex interactions
between listed nonenzymatic and enzymatic mechanisms.
Carbapenems (imipenem [IPM], and to a certain degree
also meropenem [MEM] and doripenem [DOR]) enter into
the periplasmic space of bacteria through the OprD outer
membrane porin. Thus, reduced expression of OprD porin
mainly leads to imipenem resistance.30 Although the loss of
specific porin channels also increases minimum inhibitory
concentrations (MICs) of meropenem and doripenem, clin-
ical resistance to these drugs is thought to require additional
mechanisms such as upregulation of efflux pump expression
or overproduction/mutation of AmpC cephalosporinase.18,24
MexAB-OprM, MexCD-OprJ, and MexEF-OprN efflux
pump systems have broad substrate specificity, extruding
many antibiotic classes, including b-lactams, fluoroquinolones,
and aminoglycosides.36 Besides, redundancy frequently
exists among transporters—fluoroquinolones, for example,
are universal substrates for the main efflux systems.
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Over the previous decade, an increasing number of P.
aeruginosa isolates producing carbapenem-hydrolysing en-
zymes have been reported from various parts of the world,
including Europe, and four major families of metallo-b-
lactamases (MBLs) have been identified (VIM, IMP, SPM,
and GIM families). Although it is still rare, global prevalence
of MBL-expressing P. aeruginosa strains has increased stea-
dily, and isolates expressing VIM enzymes have been detected
in different regions of Croatia.3,35 In addition, Klebsiella
pneumoniae carbapenemase (KPC)-producing P. aeruginosa
isolates were recently reported in Europe.14
Recently, an increase in the prevalence of carbapenem-
resistant P. aeruginosa isolates has been observed at the
Clinical Hospital Centre Rijeka. This study was conducted
to determine the underlying mechanisms that conferred the
carbapenem resistance phenotype, and to examine the clonal
relationships of isolates.
Materials and Methods
Bacterial isolates
A total of 38 nonduplicate P. aeruginosa isolates with
reduced susceptibility to at least one of the carbapenems
were collected from hospitalized patients at Clinical Hos-
pital Centre Rijeka, during the second half of 2009 and the
beginning of 2010, and identified by API 20NE (bioMe´r-
ieux, Marcy l’Etoile, France). Isolates were collected from
patients admitted to several wards (two intensive care units
[ICUs], cardiology, gastroenterology, neurology, neurosur-
gery, pulmonology, pediatric, and surgery) of three geo-
graphically distinct hospital locations. Strains isolated from
endotracheal aspirates, sputum, urine, and pus were ser-
otyped by slide agglutination using commercially obtained
antisera according to recommendation of the manufacturer’s
protocol (Bio-Rad, Marnes-la-Coquette, France).
Antimicrobial susceptibility
For antimicrobial susceptibility testing (AST), strains
were cultured at 37C for 24 hr in Mueller–Hinton broth
(MHB; BD Difco, Le Pont de Claix Cedex, France), and
inoculates were prepared in the same medium at a density
adjusted to a 0.5 McFarland turbidity standard. P. aerugi-
nosa ATCC 27853 was used as a quality control strain. MIC
of the antibiotics was determined using Etest according to
the manufacturer’s and EUCAST guidelines.39 MIC break-
points were derived from EUCAST.39 The following antibiotics
were tested: MEM, IPM, DOR, amikacin (AMK), gentami-
cin (GEN), tobramycin (TOB), ciprofloxacin (CIP), cefepime
(FEP), ceftazidime (CAZ), and colistin (CST) from the AB
Biodisk (Solna, Sweden). MIC50 and MIC90 levels were
defined as the lowest concentration of the antibiotic at which
50% and 90% of the isolates were inhibited, respectively.
The inducible AmpC activity was tested phenotypically
using disk approximation technique. Imipenem (10mg), ce-
foxitin (30 mg), and amoxicillin-clavulanate (20/10 mg) disks
are used as the inducing antibiotics, and ceftazidime (30mg)
disks (Bio-Rad) as the reporter antibiotic. Disks were ap-
plied by use of an applicator at a distance of 20mm, and any
obvious blunting or flattening of the zone of inhibition be-
tween the ceftazidime disk and the inducing antibiotic was
interpreted as a positive result for AmpC.
Inhibitory effects of CCCP against efflux pumps
Efflux pump overexpression was initially screened for by
testing susceptibility to imipenem and meropenem in the
presence and absence of an efflux pump inhibitor, carbonyl
cyanide-m-chlorophenylhydrazone (CCCP). AST was per-
formed by agar dilution method with and without CCCP
added in MH agar at concentrations of 12.5mM. Drugs and
CCCP were obtained from Sigma-Aldrich Corp. (St. Louis,
MO).
Detection of MBLs
Screening for MBL production was done by Etest MBL
commercial strips according to the manufacturer’s instruc-
tions (AB Biodisk). The Etest MBL strip contains a double-
sided dilution range of imipenem and imipenem combined
with EDTA. The test was considered positive if a reduction
of imipenem MIC by threefold or more twofold dilutions
was observed in the presence of EDTA.
Polymerase chain reaction (PCR) analyses for detection
of MBLs and KPC carbapenemase genes were carried out
for all strains. Template DNA was prepared by boiling
method. Specific primers to detect the presence of: blaIMP,
blaVIM, blaGIM and blaSPM-1, blaNDM, and blaKPC were used
in PCR mixtures (50 ml final volumes) containing 25ml of
PCR master mix, 20 ml of ultrapure water, 1ml of each pri-
mer (Sigma-Aldrich), and 3 ml of template DNA. All prim-
ers are listed in Table 1.
Pulsed-field gel electrophoresis
P. aeruginosa strains were genotyped by pulsed-field gel
electrophoresis (PFGE) of SpeI restricted fragments. PFGE
was performed as previously described,16 with our modifi-
cations. Briefly, bacteria were grown overnight in BHI
medium, washed, resuspended in saline EDTA (SE) buffer
(75mM NaCl, 25mM EDTA), and embedded in agarose by
mixing 150 ml of bacterial suspension and 150 ml of 2% low
melting point agarose solution in SE buffer. Agarose plugs
were incubated overnight in Lysis solution 1 (6mM Tris-
HCl pH 7.5, 100mM EDTA pH 7.5, 1M NaCl, 0.5% Brij
58, 0.2% sodium dodecyl sulfate [SDS], 0.5% lauryl sar-
cosine, and 0.5mg/ml lysosim), washed twice for 15min
with 50mM EDTA pH 9.5, and then incubated overnight in
Lysis solution 2 (1% lauryl sarcosine, 500mM EDTA pH
9.5, and 0.5mg/ml proteinase K). Agarose plugs were wa-
shed with TE buffer (10mM Tris pH 7.5, 10mM EDTA pH
7.5) thrice for 30min at 4C. After this, the wash plugs
were sliced in *1–2mm slices, that were digested with
20U of SpeI restriction endonuclease (Fermentas, Vilnius,
Lithuania) at 37C overnight, and then transferred to
0.5 ·TBE buffer, loaded on the comb, and run in 1.2%
agarose gel in CHEF-DR III pulsed-field electrophoresis
system (Bio-Rad, Hercules, CA) at 6 V/cm, 120 field angle,
14C, with initial and final switch times between 3 and
36 sec for 26 hr. Gels were analyzed with GelCompar II
software (Applied Maths NV, Sint-Martens-Latem, Bel-
gium). A dendrogram showing clonal relationship of the
isolates was constructed using the unweighted-pair-group
method of the arithmetic average clustering with the Dice
similarity coefficient (optimization 1%, tolerance 1%, and
tolerance change 0.5%).
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Real-time RT-PCR
The expression of the genes coding for the efflux pumps
proteins MexAB, MexCD, MexEF, as well as outer mem-
brane protein OprD, was analyzed using reverse-transcription
quantitative PCR (RT-qPCR). Total RNA was extracted
from all strains using the High Pure RNA Isolation kit
(Roche, Mannheim, Germany), and reverse transcribed into
cDNA using the first-strand cDNA Synthesis Kit for RT-
PCR (Roche). The latter was subjected to qPCR using
LightCycler FastStart DNA Master SYBR Green I (Roche)
in the LightCycler 2.0 LC (Roche). Relative expression of
the efflux pumps, and oprD genes in clinical isolates was
determined by comparing mRNA levels of the genes in the
clinical isolates and control P. aeruginosa ATCC 27853
strain, which is sensitive to all tested antibiotics. The gene
coding for the ribosomal protein S12 (rpsl) was used as a
reference gene for normalizing the transcription levels of
target genes. Relative quantification was done by compar-
ative Ct method (2
-DDCt).23 According to previously pub-
lished criteria, isolates were considered as having MexAB
efflux pump overexpression if the mRNA level of mexB
gene was at least threefold higher in the isolate than in
reference ATCC 27853 strain, negative if lower than two-
fold, and borderline if between twofold and threefold.4 Iso-
lates were considered positive for MexCD and MexEF
overexpression if the level of mRNA for mexD or mexF were
at least 10-fold higher than in reference ATCC strain, nega-
tive if lower than 5-fold, and borderline if between 5- and
10-fold.4 Isolates were considered having reduced oprD ex-
pression if the mRNA levels were more than twofold lower
than in the reference ATCC strain 27853.29 We used primers
for RT-qPCR that amplified the region of oprD mRNA be-
tween nt. 516 and 718 of oprD sequence from PAO1 (cor-
responds to the region between aa. 172 and 238 in the OprD
protein). Primers used for qPCR are listed in Table 1.
Results
Clinical characteristics and antimicrobial
susceptibility of isolates
Most of the isolates were obtained from patients of the
ICUs (70%), and mostly isolated from endotracheal aspirates
(87%). Serotype O:11 was the most prevalent, accounting for
*47% of the isolates, followed by serotype O:1 (29%). Six
isolates were the rare serotypes O:6, O:7/8, O:15, and O:16,
while two isolates were untypeable or polyagglutinable (Fig.
1). All of 38 isolates were resistant to meropenem and dor-
ipenem, and in general, intermediary resistant to imipenem
(Table 2). Nine isolates were imipenem resistant. Almost all
isolates displayed resistance to the other groups of anti-
pseudomonas antibiotics, with 79% being MDR (30 out of 38
isolates). All isolates belonging to different serotypes were
MDR P. aeruginosa, except seven O:1 isolates that showed
sensitivity to the most of the tested antibiotics. P. aeruginosa
strains demonstrated high-level resistance to gentamicin
(79%), amikacin (66%), tobramycin (79%), and ciprofloxacin
(71%). Ten strains (26%) showed AmpC b-lactamase activity
by phenotypic testing. Table 3 depicts the MIC50 and MIC90
values of clinical isolates. According to MIC90 values, colistin
was found to be the most active agent (0.38mg/ml), followed
by cefepime (8mg/ml) and ceftazidime (12mg/ml). The MIC
values of colistin were below the resistance breakpoints.
Detection of MBLs
Although eight isolates were suspected to be MBL posi-
tive by the MBL Etest, PCR analyses did not detect MBLs
Table 1. Primers Used for Polymerase Chain Reaction and Reverse-Transcription Quantitative PCR
Gene Primer Oligonucleotide sequence Reference
VIM-1a VIM-1-F CAGATTGCCGATGGTGGTTGG Lauretti et al.20
VIM-1-R AGGTGGGCCATTCAGCCAGA
IMPa IMP-A GAAGGYGTTTATGTTCATAC Watanabe et al.42
IMP-B GTAMGTTTCAAGAGTGATGC
SPMa SPM-F CCTACAATCTAACGGCGACC Toleman et al.40
SPM-R TCGCCGTGTCCAGGTATAAC
GIMa GIM-F AGAACCTTGACCGAACGCAG Castanheira et al.5
GIM-R ACTCATGACTCCTCACGAGG
NDM-1a NDM-F AATGGAATTGCCCAATATTATGC Yong et al.44
NDM-R CGAAAGTCAGGCTGTGTTGC
KPCa KPC-F TGTCACTGTATCGCCGTC Yigit et al.43
KPC-R CTCAGTGCTCTACAGAAAACC
Ribosomal protein S12
reference geneb
rpsL-1 GCTGCAAAACTGCCCGCAACG Islam et al.12
rpsL-2 ACCCGAGGTGTCCAGCGAACC
oprDb oprD-F GCTCGACCTCGAGGCAGGCCA Rodriguez-Martinez
et al.34oprD-R CCAGCGATTGGTCGGATGCCA
mexABb mexB-1 CAAGGGCGTCGGTGACTTCCAG Islam et al.12
mexB-2 ACCTGGGAACCGTCGGGATTGA
mexCDb MxD-F GGACGGCTCGCTGGTCCGGCT Rodriguez-Martinez
et al.34MxD-R CGACGAAGCGCGAGGTGTCGT
mexEFb mexF-F CGCCTGGTCACCGAGGAAGAGT El Amin et al.8
mexF-R TAGTCCATGCCTTGCGGGAAGC
aPrimers used for PCR.
bPrimers used for RT-qPCR.
RT-qPCR, reverse-transcription quantitative polymerase chain reaction.
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of either IMP, VIM, GIM, SPM, or NDM family (data not
shown). PCR for KPC genes was also negative.
Synergy between CCCP and carbapenems
A degree of synergy was observed between efflux pump
inhibitor and tested carbapenems. The MIC levels of mer-
openem showed twofold to eightfold reduction in the presence
of CCCP in 32 (84%) out of 38 isolates, but CCCP did not
allow complete restoration ofmeropenem activity according to
relatively high meropenemMICs (8–64mg/ml). MIC levels of
imipenem showed mainly a twofold reduction in the presence
of CCCP in 22 (58%) out of 38 isolates (data not shown).
Pulsed-field gel electrophoresis
Among 38 isolates, obtained mainly from patients of ICU,
and mostly isolated from respiratory specimens, PFGE
analysis revealed 35 distinct profiles (Fig. 1). Isolates were
grouped in five clusters based on > 80% similarity criterion,
FIG. 1. Dendrogram showing the clonal relationship of Pseudomonas aeruginosa clinical strains, generated from the
PFGE profiles. C, cardiology; GE, gastroenterology; ICU, intensive care unit; N, neurology; NS, neurosurgery; P, pul-
monology; PED, pediatric; PFGE, pulsed-field gel electrophoresis; SUR, surgery; U, untypeable.
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with three singleton strains. The largest cluster designated C
comprised 22 out of 38 isolates (58%). There were two more
clusters (A, B) comprising four isolates, one cluster with
three, and one with two isolates. The dominant cluster C
consisted mainly of O:11 isolates (77%) found in ICU-2,
and neurosurgery, while cluster A consisted entirely of O:1
isolates (100%) observed only in ICU-1. Cluster B was more
heterogeneous, consisting of O:7/8, O:15, and O:16 isolates.
Real-time RT-PCR
The expression of mexB, mexD, mexF, and oprD genes
was measured using real-time PCR. Significant (the mRNA
level of oprD of the isolate less than 50% of the mRNA
level in reference ATCC strain) downregulation of oprD
expression was observed in 87% (31 out of 38) of isolates
(Table 4). Whether the lower expression of oprD was due to
Table 2. Antimicrobial Susceptibility of Pseudomonas aeruginosa Clinical Isolates
MIC (lg/ml)
Straina Sero type IPM MEM DOR CAZ FEP GEN AMK TOB CIP CST
2 O1 8 > 32 4 4 8 3 4 1.5 0.047 0.19
5 O1 12 > 32 6 2 3 1.5 3 0.75 0.19 0.25
6 O7/8 4 > 32 4 2 2 24 4 24 0.19 0.38
9 O1 8 > 32 6 3 4 3 4 2 0.38 0.25
10 O1 8 > 32 6 2 3 1.5 3 1 0.25 0.032
11 O11 8 > 32 8 4 4 96 12 24 > 32 0.125
14 O11 8 > 32 24 3 3 > 256 16 32 > 32 0.19
15 O11 4 > 32 4 3 4 96 192 > 256 24 0.19
16 O1 6 16 12 3 4 128 12 32 > 32 0.25
18 O11 8 > 32 12 6 6 > 256 32 96 > 32 0.125
19 O6 6 > 32 16 6 4 > 256 24 48 > 32 0.25
20 O1 8 > 32 12 24 8 > 256 16 48 > 32 0.25
23 O11 8 16 8 48 6 > 256 16 64 > 32 0.38
25 O11 8 > 32 32 4 4 > 128 12 32 > 32 0.25
26 O11 8 > 32 12 4 4 > 256 24 48 > 32 0.19
29 O11 4 > 32 12 6 3 64 12 32 > 32 0.38
31 O11 8 > 32 12 8 4 96 12 48 > 32 0.25
32 O11 8 > 32 16 6 6 > 256 12 48 > 32 0.19
33 O1 12 > 32 3 2 2 3 8 1.5 0.25 0.125
35 O1 12 > 32 32 2 8 2 8 2 0.25 0.25
37 O11 8 > 32 12 4 4 > 256 24 64 > 32 0.19
39 O11 6 > 32 8 12 3 > 256 24 64 > 32 0.125
40 O1 12 12 3 1 2 > 256 8 96 > 32 0.19
42 O15 8 > 32 6 3 3 24 4 16 0.5 0.25
43 O11 6 8 8 1.5 3 > 256 4 48 > 32 0.25
47 O7/8 6 > 32 8 3 2 16 2 16 0.094 0.19
48 O11 8 > 32 8 3 3 192 16 64 > 32 0.19
49 O11 6 > 32 8 3 3 192 12 96 > 32 0.25
50 O11 8 > 32 8 4 6 64 64 > 256 > 32 0.19
51 O11 6 > 32 4 4 3 64 12 64 > 32 0.25
52 O16 6 > 32 4 0.25 1.5 16 3 12 0.064 0.125
56 O7/8 64 > 32 6 6 6 > 256 24 48 > 32 1
57 O1 8 > 32 4 4 12 3 8 1.5 0.25 0.25
58 O4 12 > 32 3 12 8 4 12 2 2 0.094
60 O1 12 > 32 24 256 48 > 256 12 > 256 24 0.125
61 O11 8 > 32 8 3 3 64 96 > 256 > 32 0.25
62 U 16 > 32 24 4 6 > 256 12 32 > 32 0.19
63 U 12 > 32 24 8 6 > 256 16 64 > 32 0.25
aAmpC-producing strains are underlined; multidrug-resistant strains are indicated in boldface.
AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; DOR, doripenem; FEP, cefepime; GEN, gentamicin; IPM,
imipenem; MIC, minimum inhibitory concentration; MEM, meropenem; TOB, tobramycin; U, untypeable.
Table 3. MIC Range, MIC50, MIC90 (in mg/ml),
and Susceptibility of P. aeruginosa
Clinical Isolates
MIC (interpretation)
Antibiotic MIC range MIC50 MIC90
Susceptibility
(%)
IPM 4 to > 64 8 (I) 12 (R) 5
MEM 6 to > 32 > 32 (R) > 32 (R) 0
DOR 2 to > 32 8 (R) 32 (R) 0
CAZ 0.25 to > 256 4 (S) 12 (R) 87
FEP 1.5 to > 48 4 (S) 8 (S) 95
GEN 1.5 to > 256 28 (R) 256 (R) 21
AMK 2 to > 192 12 (I) 24 (R) 34
TOB 0.75 to > 256 48 (I) 256 (R) 21
CIP 0.047 to > 32 > 32 (R) > 32 (R) 29
CST < 0.032 to 1 0.25 (S) 0.38 (S) 100
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the gene ORF mutation, promoter variation, or regulator
mutation was beyond the scope of this study. The genes
mexB, mexD, and mexF were upregulated in 45%, 11%, and
26% isolates, respectively. Simultaneous upregulation of
two efflux pump genes (mexB and mexF) was identified in
five isolates, while one isolate showed overexpression of all
three efflux pumps (Table 4). We considered the isolates
with the borderline values of overexpression of mexB,
mexD, and mexF as having upregulated efflux pump ex-
pression, as the results of synergy between efflux pump
inhibitor CCCP and carbapenems showed that almost all of
the isolates with borderline values of efflux pump mRNAs
showed the reduction of MICs for imipenem, meropenem,
or both in the presence of CCCP (data not shown). There
was no correlation between antibiotic susceptibility pheno-
type and expression of efflux pump genes.
Discussion
The aim of this study was to detect the resistance mecha-
nisms and clonal relatedness in carbapenem-resistant P.
aeruginosa that caused hospital outbreak in several wards at
the Clinical Hospital Center Rijeka, a tertiary care, university
Croatian hospital with 1,191 inpatients and 26 ICU beds. All
isolates were resistant to meropenem and doripenem, and in
general, intermediary resistant to imipenem, 79% being
MDR. Although isolates with acquired carbapenemases have
been reported recently in Croatia and adjacent regions,3,9,15
this resistance mechanism was not detected in clinical strains
studied here. Five strains were positive for MBL in pheno-
typic test but did not yield any product with primers specific
for MBL. It is possible that they were false positive in phe-
notypic test or they posses some rare type of MBL such as
AIM, DIM, or FIM that was not sought in this study.
Efflux activity was initially screened for by testing sus-
ceptibility to carbapenems with and without an efflux pump
inhibitor. Efflux pump inhibitor reverts MICs of resistant
strains to those that do not express efflux systems.41 In this
study, synergy observed between CCCP and meropenem
suggested that its extrusion by the efflux systems contributes
to the resistance. Molecular method (RT-qPCR) used to
detect the expression of efflux pumps and OprD porin genes
revealed overproduction of one or more putative efflux
pumps genes in 63% of the isolates. In fact, most of the
examined clinical isolates had simultaneous downexpression
of oprD and increased efflux pumps expression, in addition
to AmpC production detected by phenotypic method. Al-
though resistance to meropenem in P. aeruginosa is princi-
pally efflux pump mediated, oprD downregulation observed
in 87% of strains could explain the relatively high mer-
openem MICs in the presence of CCCP. It could be postu-
lated that both, overexpression of efflux systems, identified
in more than half of the isolates, and downregulation of oprD
expression, observed in the most of the strains, contributed to
meropenem resistance. There was no correlation between
antibiotic susceptibility phenotype and expression of efflux
pump genes. However, in half of the isolates with reduced
susceptibility to imipenem, besides the downregulated oprD
expression, increased expression of at least one of the efflux
pumps was observed. Although other studies have shown
that beside ceftazidime, imipenem is the least affected among
b-lactams by efflux pumps,28 efflux mechanism and/or AmpC
production are possibly involved in the imipenem resistance
of several strains with normal oprD expression. It is known
that imipenem consumption select loss of porins, while
meropenem utilization leads to efflux pumps hyperexpres-
sion.18,25,30,36 Before and during the outbreak in our hospital,
especially in ICUs, twice higher consumption of meropenem
in comparison to imipenem was observed, explaining more
frequent meropenem resistance in Pseudomonas isolates.
Although doripenem was not used in our hospital, all isolates
Table 4. Expression of Genes mexB, mexD, mexF,
and oprD in P. aeruginosa Clinical Strains
Relative to the Respective Referent
P. aeruginosa ATCC 27853 Strain
Gene transcription
(fold P. aeruginosa ATCC)
Straina mexB mexD mexF oprD
Imipenem
susceptibility
ATCC 1.00 1.00 1.00 1.00 S
2 7.41b 2.20 2.84 0.04b I
5 3.68b 5.85c 12.56b 0.21b R
6 0.59 0.68 4.38 0.32b S
9 5.83b 2.01 1.62 0.05b I
10 4.75b 4.89 18.58b 0.48b I
11 2.64c 1.28 4.45 0.07b I
14 1.23 1.68 16.26b 0.07b I
15 1.22 0.57 3.80 0.12b S
16 2.06c 2.04 3.66 0.27b I
18 2.58c 3.45 5.33c 0.29b I
19 3.11b 3.19 3.64 0.34b I
20 2.74c 2.39 11.21b 0.47b I
23 1.99 1.26 4.65 0.13b I
25 2.57c 0.84 3.54 0.12b I
26 1.33 1.46 6.20c 0.23b I
29 1.95 1.24 7.32c 0.15b S
31 1.31 0.77 1.27 0.13b I
32 2.61c 0.59 2.02 0.13b I
33 5.79b 1.50 6.72c 0.08b R
35 6.66b 0.58 4.44 0.86 R
37 1.42 0.86 1.87 0.14b I
39 1.17 0.25 0.81 0.09b I
40 0.70 1.43 4.36 0.33b R
42 0.37 2.23 1.01 0.31b I
43 0.67 2.08 4.29 2.59 I
47 0.98 5.24c 2.88 2.63 I
48 1.69 2.56 4.63 0.28b I
49 3.74b 2.76 3.80 0.43b I
50 2.74c 1.33 4.34 0.14b I
51 2.59c 3.96 6.88c 0.29b I
52 0.83 4.97 14.89b 0.68 I
56 0.56 2.76 4.29 0.84 R
57 2.22c 3.21 3.53 1.48 I
58 0.39 6.12c 3.40 0.99 R
60 0.80 18.06b 2.48 0.04b R
61 0.59 3.45 4.93 0.25b I
62 1.11 0.74 3.99 0.10b R
63 1.70 7.48c 4.98 0.23b R
aAmpC-producing strains are underlined.
bIncreases in gene expression of mexD and mexF >10-fold,
increases in gene expression of mexB >3-fold, and decreases in gene
expression of oprD<2-fold were taken as positive.
cIncreases in gene expression of mexD and mexF between 5- and
10-fold, and increases in gene expression of mexB between 2- and
3-fold were taken as borderline.
I, intermediate; R, resistant; S, susceptible.
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were resistant to doripenem according to EUCAST break-
points. In accordance with results of Riera et al. in vitro
study, we noticed lower doripenem than meropenem MICs,
but better activity of doripenem than meropenem could only
be speculated.33
The susceptibility to ceftazidime and also to cefepime
observed in most of the carbapenem-resistant isolates im-
plies the absence of resistance mechanisms against these b-
lactams. It has been previously demonstrated that strains
with downexpressed OprD porins may remain susceptible to
b-lactam agents that penetrate via other porins.32 Apart from
carbapenem resistance, efflux pumps of P. aeruginosa are
known to be an extremely important cause of multidrug
resistance in the hospital settings.25,36
An increase in the prevalence of carbapenem-resistant
P. aeruginosa observed at our hospital during the previous
decade can be partly attributed to widespread empirical use
of ciprofloxacin, which was the most commonly used anti-
biotic. Ciprofloxacin consumption, expressed as the number
defined daily doses (DDDs) per 100 bed days (BD), in-
creased about 41% from 2006 (2.35 DDD/100BD) to 2010
(3.30 DDD/100BD). We assume that increased consumption
of ciprofloxacin in our hospital led to not only increased
quinolone but also carbapenem resistance. Previous clinical
studies support this concept. Restriction of ciprofloxacin in a
teaching hospital was associated to decreased resistance of
P. aeruginosa isolates to antipseudomonal carbapenems as
reported by Lewis et al.22 Cook et al. showed in an obser-
vational study correlation of ciprofloxacin use with the
percentage of P. aeruginosa isolates resistant to the mer-
openem and imipenem.6 Several other studies have sug-
gested that the use of fluoroquinolones may select strains
resistant not only to quinolones but also to other structurally
unrelated antibiotics.7,21 Authors reported selection of mu-
tants that overexpress the MexAB-OprM pump during the
course of quinolones or cephalosporins therapy.45 In Pseu-
domonas spp., induction of efflux pumps is associated with
reduced levels of OprD porin. Therefore, quinolone use may
lead to cross-resistance to carbapenems, either by increased
efflux (meropenem and doripenem) or by decreased porin
entry (imipenem, meropenem, and doripenem).
Our study recognized serotype O:11 as an important
problem in our hospital because of the resistance to multiple
antibiotics. Current evidence suggests that in Croatia, sim-
ilarly to the other Mediterranean countries, most P. aeru-
ginosa strains belong to the O:11 serotype frequently
associated with the international epidemic clone ST235.10,26
The next most frequent serotype in our hospital was O:1.
Interestingly, while all isolates belonging to O:11 and other
observed serotypes were MDR, the majority of O:1 isolates
maintained sensitivity to the most of the antibiotics. In this
study, PFGE analysis defined five major clusters of isolates.
The largest cluster C correlated with O:11 serotype, and
resistance pattern to gentamicin, tobramycin, and cipro-
floxacin as all the isolates from the largest cluster C were
resistant, while the isolates from clusters A, B, and D were
susceptible to those three antibiotics. Cluster A consisted
entirely of antibiotic-sensitive O:1 isolates. Unlike clusters
A and C, cluster B was more heterogeneous comprising O:7/
8, O:15, and O:16 isolates. This suggests that serotyping can
lead to a misleading classification of the isolates. The in-
adequacy of serotyping to confirm a clonal relation among
MDR isolates has been previously reported.13,31,35 It has
been demonstrated that antimicrobial therapy was able to
induce serotype conversion in P. aeruginosa, leading to
clustering of isolates with different serotypes.17
Although downregulation of OprD porin was found in all
isolates belonging to A and C clusters, there was no correlation
between PFGE type and antibiotic susceptibility to carbape-
nems. Our molecular epidemiological study has revealed that
two clones, included in clusters A and C, caused outbreaks in
ICUs. Distribution of strains showed correlation with the other
locations of hospital departments where the isolates were
collected, which implies that most of the infections are due to
spread of several clones within the hospital.
Many P. aeruginosa outbreaks in hospitals of environ-
mental origin have been reported in the previous few
years.1,2,11,19,37 Although we performed extensive environ-
mental sampling, we were unable to identify an environ-
mental source of infection. P. aeruginosa strains were
isolated from two environmental specimens collected—
cleaning mop and hand washing tap, but the isolates differed
from the outbreak strains in both antibiotic resistance and
PFGE profiles (data not shown). However, clustering of
isolates may be due to either patient-to-patient transmission
or a common source of acquisition (e.g., contaminated re-
spiratory therapy equipment).
Hospital infections caused by MDR P. aeruginosa are
frequently life threatening due to lack of effective antimi-
crobial treatment. Our study showed oligoclonal outbreak of
P. aeruginosa with several mechanisms involved in carba-
penem resistance—the low outer membrane permeability
combined with efflux system overexpression. Increased
consumption of ciprofloxacin and carbapenems, especially
meropenem, has probably contributed to the emergence and
spread of these mechanisms. Availability of local epidemi-
ological data and bacterial resistance mechanisms are nec-
essary to decrease the risk of treatment failure, and aid in
establishing infection control programs, as well as to pre-
vent global dissemination of the resistant strains.
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